Oxycodone Hydrochloride

Vancouver, British Columbia--(News - March 30, 2026) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H0) (" PreveCeutical " or the " Company "), a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature-identical products, is pleased to announce the appointment of Dr. Raj S. Pruthi, MD, MHA, FACS, to its Board of Directors. Dr. Pruthi is an accomplished physician-scientist and executive with more than 20 years of experience spanning academic medicine, global pharmaceutical leadership, and biotechnology innovation. In his new role, he will contribute to shaping the Company's clinical development strategy and advancing key initiatives, including its Sol-gel program, Nature Identical™ peptide platform, non-addictive pain management therapies, and dopamine-based treatments targeting Parkinson's disease. Bringing extensive experience in clinical trial design, regulatory strategy, and organizational leadership, Dr. Pruthi has worked closely with global regulatory agencies such as the FDA and EMA and has been actively involved in capital markets initiatives. He currently serves as Chief Medical Officer of Relmada Therapeutics, Inc., a position he has held since June 2025. There, he leads development of the NDV-011 bladder cancer program, including a Phase 2 study and preparations for a global Phase 3 registrational trial expected to commence in early 2026. His responsibilities have included stakeholder engagement, trial execution, and collaboration with investors and regulatory authorities. He also played a central role in financing efforts that generated over $100 million through a public offering and an additional $160 million via a PIPE transaction. From 2022 to 2024, he held senior leadership roles in oncology at Johnson & Johnson Innovative Medicine (Janssen), where he contributed to late-stage clinical development, including multiple Phase 3 trials and regulatory submissions. His work supported approvals from both the FDA and EMA, including the approval of TAR-200 in 2025 for certain bladder cancer patients. He also incorporated patient-reported outcomes and digital health tools into clinical study designs. Before transitioning to industry, Dr. Pruthi spent over two decades in academia, serving as a tenured professor and Chair of Urology at leading institutions such as the University of California, San Francisco and the University of North Carolina. He is recognized for pioneering robotic surgical techniques and has shared his expertise internationally. His academic record includes more than 220 peer-reviewed publications, numerous book chapters, and hundreds of scientific presentations, along with leadership roles in national clinical guideline development. Dr. Pruthi received his medical degree from Duke University, completed his surgical and urology training at Stanford University, and earned a Master of Health Administration from the University of North Carolina at Chapel Hill. He is board-certified in urology and a Fellow of the American College of Surgeons. "I am excited to join PreveCeutical at an important stage of its evolution," said Dr. Pruthi. "The Company's commitment to developing innovative therapies based on natural and nature-identical compounds aligns closely with my professional interests. I look forward to working with the team to advance its clinical programs and address significant unmet medical needs." Stephen Van Deventer, Chairman and CEO of PreveCeutical, added: "We are very pleased to welcome Dr. Pruthi to our Board. His extensive experience in clinical development, regulatory strategy, and leadership will be invaluable as we continue to advance our pipeline. His expertise strengthens our ability to deliver innovative therapies and achieve meaningful progress across our programs." About PreveCeutical Medical Inc. PreveCeutical is a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature identical products. PreveCeutical aims to be a leader in preventive health sciences and currently has five research and development programs, including: dual gene therapy for curative and prevention therapies for diabetes and obesity; the Sol-gel Program; Nature Identical™ peptides for treatment of various ailments; nonaddictive analgesic peptides as a replacement to the highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury). For more information about PreveCeutical, please visit our website or follow us on Twitter and Facebook . On Behalf of the Board of Directors, PreveCeutical Medical Inc. " Stephen Van Deventer" Chairman & Chief Executive Officer For further information, please contact: Stephen Van Deventer (604) 306-9669 info@PreveCeutical.com Forward-Looking Statements: This news release contains forward-looking statements and forward-looking information (collectively, "forward-looking statements") within the meaning of applicable Canadian and U.S. securities legislation, including the United States Private Securities Litigation Reform Act of 1995. All statements in this news release that are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations and orientations regarding the future, including, without limitation, the continued research interests of PreveCeutical, PreveCeutical's anticipated business plans, and its prospects of success in executing its proposed plans. Often, but not always, forward-looking statements can be identified by words such as "will", "pro forma", "plans", "expects", "may", "should", "budget", "schedules", "estimates", "forecasts", "intends", "anticipates", "believes", "potential", "proposes" or variations of such words including negative variations thereof and phrases that refer to certain actions, events or results that may, could, would, might or will occur or be taken or achieved. Forward-looking statements are based on certain assumptions regarding PreveCeutical, including expected growth, results of operations, including PreveCeutical's research and development activities, performance, industry trends, growth opportunities, that PreveCeutical will be granted requisite expedited approvals by world health, retain and attract qualified research personnel and obtain and/or maintain the necessary intellectual property rights needed to carry out future business activities. Actual results could differ from those projected in any forward-looking statements due to numerous factors including, risks and uncertainties relating to: complexities and delays in connection with research and development activities and the actual results of research and development activities; the ability of PreveCeutical to, among other things, protect its respective intellectual property, obtain any required governmental, regulatory or stock exchange approvals, permits, consents or authorizations required, including Canadian Securities Exchange acceptance of any planned future activities and obtaining expedited requisite approvals from world health agencies; and the ability of PreveCeutical to commercialize products, pursue business partnerships, complete their research programs as planned, and obtain the financing required to carry out their planned future activities. Other factors such as general economic, market or business conditions or changes in laws, regulations and policies affecting the biotechnology or pharmaceutical industry may also adversely affect the future results or performance of PreveCeutical. These forward-looking statements are made as of the date of this news release and, unless required by applicable law, PreveCeutical assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in these forward-looking statements. Although PreveCeutical believes that the statements, beliefs, plans, expectations, and intentions contained in this news release are reasonable, there can be no assurance that those statements, beliefs, plans, expectations, or intentions will prove to be accurate. Readers should consider all of the information set forth herein and should also refer to other periodic reports provided by PreveCeutical from time-to-time. These reports and PreveCeutical's filings are available at . Neither the Canadian Securities Exchange (CSE or CNSX Markets), its Regulation Services Provider (as that term is defined in policies of the CSE), nor any other regulatory authority accepts responsibility for the adequacy or accuracy of this release. Any link in this press release to external information or other resources is provided for reference only, and such information or resources might change from time to time, and may include forward-looking statements as described above, and are subject to the above disclaimers under this heading forward-looking statements. Readers are cautioned that forward-looking statements are not guarantees of future performance or events and, accordingly, are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty of such statements. To view the source version of this press release, please visit

3月21日，重庆渝州宾馆，一场汇聚专家、政企学界代表的思想盛宴如期而至。以“正源出新·生态共融”为主题的科技创新大会上，仝小林、田金洲、陈士林、高月、庾石山等国内顶尖医药专家齐聚一堂，国医大师廖品正、林天东等行业泰斗也来到现场。 这一天，首个“太极品牌日”与现代中药产业大脑正式发布，多项产学研医合作项目集中签约。作为中医药行业领军企业、本次大会承办方的国药太极以一场高规格的科创盛会，集中展现“十四五”以来的创新实践，更以此为新起点，稳步向“世界一流中药企业”的宏伟愿景迈进。 ▲现代中药产业大脑发布仪式。 大会赋能 多项重磅成果落地渝州 本次大会由重庆医药行业协会主办、国药太极承办。大会汇聚专家学者、政企学界代表300余人，以构建中医药创新生态为核心，通过多方合作、项目发布、主题交流等一系列举措，共同推动中医药创新资源整合、成果转化落地。 大会核心环节，多项科创与产业融合成果集中落地。国药太极医药研究院副院长蒲道俊作“中药创新研究”院士工作站成果报告，分享院士工作站在中药资源数字化、创新药物研发等领域的系列突破。产学研医签约仪式上，国药太极与四川大学华西医院、南京中医药大学等多家单位签约，打通创新研发、临床应用与产业转化全链条。 与此同时，两大里程碑事件同步发布：首个“太极品牌日”正式发布，国药太极将每年3月21日定为专属品牌日，开启面向全球的品牌焕新蓝图；由重庆市经济信息委统筹、涪陵区政府揭榜挂帅、国药太极建设运营的现代中药产业大脑正式发布，联动中国联通、华为等企业构建数字化服务矩阵，助力重庆打造现代中医药产业高地。 此外，大会设置多场前沿主题报告，专家学者围绕中成药研发应用、阿尔茨海默病药物研究、濒危动物药材替代品研发、AI与基因组新药创制等主题分享学术成果，从技术、产业、生态多维度为中医药传承创新发展凝聚智慧。 “‘正源出新·生态共融’既是面向未来科技创新发展的宣言，更是对行业高质量发展的深刻思考。”国药太极党委书记、董事长俞敏在大会致辞中表示，国药太极将致力于构建开放协同的生态，创新产品形态、创新产出业态、创新产业生态，打造“产学研医用”一体化生态圈，助力健康中国建设。 科创攻坚 中医药研发迎来高质量突破 如何从成千上万种中药材中，快速找到治疗特定疾病的有效成分？科研人员有了“得力助手”——全球首个中药全产业链大模型“本草智库”。这个汇集了1500万条中药材基因信息、3000余万条成分与靶点互作数据的“智慧大脑”，让新药研发从“大海捞针”变为“精准导航”。 国药太极作为联合开发单位，这一数字化突破，正是其坚持科技创新的生动写照。回眸“十四五”，从数字化工具的应用，到研发平台的夯实，企业着力构建全链条创新生态，在中医药领域结出累累硕果。 2024年，与陈士林教授联合建立的“中药创新研究”院士工作站落地，陈可冀院士学术传承研究室、廖品正等国医大师传承创新工作室相继设立，“院士引领+国医传承”的双轮驱动模式基本成型。与20余家顶尖高校、科研机构的深度合作，国药太极科创中心六大技术平台的建成，为企业深耕中药赛道、精细化药赛道、切入生物药赛道，以及重塑研发体系奠定坚实基础。 创新成果正加速走向应用。2025年，太极藿香正气口服液治疗特应性皮炎、防治结肠炎等3项临床研究发表于国际权威期刊，为中药现代化提供高级别循证证据；急支糖浆作用机制研究首次从分子层面得以揭示。化药领域，盐酸羟考酮缓释片获批，在镇痛药物领域实现突破；生物药领域，GLP-1受体激动剂申报IND，实现零的突破。 市场开拓同样蹄疾步稳。2025年以来，多款明星产品在新加坡、加拿大、中国澳门等国家和地区获批上市，华盖颗粒成为澳门特别行政区药监局成立后首个获批的经典名方复方制剂，开创“澳门注册+横琴生产”新模式，为中药“走出去”蹚出新路。 ▲国药太极部分明星产品展示。 产业焕新 全链布局打造数智化新生态 技术的革新，最终要落到产业的布局上。走进太极医药城B区提取车间，计算机显示屏上，1200余套设备的运行状态实时跳动。操作员轻点鼠标，中药材的提取、浓缩全流程自动运行。这里年处理中药材可达10万吨，是国药太极“十四五”产业焕新的缩影。 “过去靠经验，现在靠数据。”一位老药工感叹。2022年太极医药城B区投运，2025年科创中心建成，依托5G专网，这个集科研、提取、制剂、包装于一体的基地，正向着“灯塔工厂”迈进。“十四五”期间，国药太极新增1家重庆市智能工厂、2家数字化车间，两大智能制造案例入选工业和信息化部优秀场景，2025年更承建起现代中药“产业大脑”。 智能制造升级的背后，是产业链的持续深耕。从源头开始，国药太极在全国七大道地产区建成20余万亩标准化种植基地，苍术、紫菀等品种获“三无一全”品牌认证。2025年重庆智慧煎配中心投运后，川渝两地日均处理处方量达3000张，患者在家就能收到智能煎煮好的汤剂。 与此同时，珍稀濒危药材领域也取得实质性突破。历经45年科研长跑，国药太极与重庆市中药研究院共同攻克冬虫夏草抚育技术，“太极虫草”2025年正式上市。从四川康定到重庆涪陵，一条珍稀濒危中药材可持续发展的产业化新路径已然铺就。 “绿色”同样是发展的底色。“十四五”期间，国药太极新创建4家国家级绿色工厂，7个光伏项目年发电达400万度。2025年，涪陵制药厂、重庆中药二厂双双入选国家级绿色工厂，4家“无废”工厂的创建，让环境效益与经济效益实现双赢。 聚焦未来 向世界一流中药企业出发 站在“十五五”开局的新起点，这场行业瞩目的科创盛会，揭开了国药太极以创新为翼，以品牌赋能，迈向世界一流的崭新篇章。 依托本次大会签约成果，国药太极将推动与科研院校、医疗机构的深度合作，加速科研成果转化落地。同时，发挥龙头企业带动作用，整合中药全产业链资源，构建“产学研医用”深度融合的创新生态，助力重庆建设具有全国影响力的生物医药产业高地，推动中医药产业化、现代化、国际化发展。 未来，国药太极科技创新将持续发力，继续深耕中药优势，扩容OTC市场，打造世界级中药品牌与超级品种集群；聚焦特色化药和生物药，构建差异化技术壁垒；精准聚焦中药治未病和慢病管理等高价值领域，创新产品开发、健康方案和专业营销。同时，以现代中药产业大脑为核心，持续推动产业数字化升级，深化“产业大脑+未来工厂”模式，加速培育中医药领域新质生产力；以首个“太极品牌日”为锚点，构建“六大系统+三大架构”品牌建设体系，打造全球IP。 从涪陵江畔的一家小药厂，到如今的中药行业“国家队”，国药太极走过了半个多世纪。站在“十五五”开局的新起点，国药太极正以更加自信、开放的姿态，秉持“正源出新，精益求精”的精神，在建设健康中国的道路上阔步前行，向着“世界一流的中药企业”目标焕新出发。 （刘洋 图片由国药太极提供）